Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angeion gets defibrillator study approval:

This article was originally published in Clinica

Executive Summary

Angeion has been granted an investigational device exemption for its Sentinel 2010 implantable cardioverter defibrillator system. The company recently received FDA permission to expand its trial of the Sentinel 200 to 25 sites. Both devices have CE marking in the European Union. The 2010 is the first Angeion defibrillator to store ECG data and has enhanced programming features.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT089388

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel